ArticleJournal of orthopaedic surgery and research2025
LINC00482 targets miR-877-3p to modulate osteogenic differentiation in fracture patients.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overexpression of LINC00472 alleviates diabetic kidney disease progression via the miR-21-5p/STAT3 axis.Renal failure · 2026Article
- Hsa_circ_0005372 function as both sponging miR-877-3p and interacting with RNA binding proteins DNMT1 to promote proliferation of human pulmonary smooth muscle cells.Translational pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the diagnostic value of LINC00482 in patients with fractures and its regulatory role in osteogenic differentiation.
methodsA total of 194 participants were enrolled, of whom 103 had fractures. Fracture occurrence was determined via X-ray examination, and 5 mL of fasting venous blood was collected from all participants. Logistic regression analysis was employed to predict risk factors influencing fracture development. Receiver operating characteristic (ROC) curves assessed the diagnostic value of LINC00482 and miR-877-3p for fractures. RT-qPCR measured gene expression, while the CCK-8 assay evaluated cell proliferation. Dual luciferase reporter assays validated interactions between the target genes. Pearson correlation analysis examined the relationship between their expression relationship in fracture patients' serum.
resultsSerum from fracture patients exhibited significantly elevated LINC00482 levels and markedly reduced levels of miR-877-3p. Both demonstrated diagnostic value in predicting fracture occurrence. LINC00482, osteocalcin (OCN), and osteopontin (OPN) were identified as risk factors for fracture development. Transfection with si-LINC00482 promoted osteoblast proliferation and differentiation, and miR-877-3p was identified as a downstream target gene of LINC00482. The miR inhibitor reduced alkaline phosphatase (ALP) activity and inhibited osteoblast proliferation and differentiation.
conclusionLINC00482 may inhibit osteoblast proliferation and osteogenic differentiation by targeting miR-877-3p, thereby impeding fracture healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.